Prognostic and Clinicopathological Significance of Transducer-Like Enhancer of Split 1 Expression in Gastric Cancer

Abstract

PurposeTransducer-like enhancer of split 1 (TLE1) is a member of the Groucho/TLE family of transcriptional co-repressors that regulate the transcriptional activity of numerous genes. TLE1 is involved in the tumorigenesis of various tumors. We investigated the prognostic significance of TLE1 expression and its association with clinicopathological parameters in gastric cancer (GC) patients.Materials and MethodsImmunohistochemical analysis of six tissue microarrays was performed to examine TLE1 expression using 291 surgically resected GC specimens from the Soonchunhyang University Cheonan Hospital between July 2006 and December 2009.ResultsIn the non-neoplastic gastric mucosa, TLE1 expression was negative. In GC, 121 patients (41.6%) were positive for TLE1. The expression of TLE1 was significantly associated with male gender (P=0.021), less frequent lymphatic (P=0.017) or perineural invasion (P=0.029), intestinal type according to the Lauren classification (P=0.024), good histologic grade (P<0.001), early pathologic T-stage (P=0.012), and early American Joint Committee on Cancer stage (P=0.022). In the Kaplan-Meier analysis, the TLE1 expression was significantly associated with longer disease-free (P=0.022) and overall (P=0.001) survival rates.ConclusionsWe suggested that TLE1 expression is a good prognostic indicator in GCs.

Clinicopathologic and Prognostic Significance of Transducin-Like Enhancer of Split 1 Protein Expression in Invasive Breast Cancer

“…This suggests an oncogenic effect of TLE1 in breast carcinogenesis. These findings are similar to those reported previously in gastric, breast, and lung cancer [161718]. …”

“…Normal gastric mucosa has no TLE1 expression. We suggested that TLE1 had an oncogenic effect in gastric cancer [16]. In a study analyzing breast tissue by IHC, TLE1 was significantly overexpressed in IBC tissues (67.4%) compared to normal breast tissue and DCIS samples [17].…”

“…As described above, the reported frequency of TLE1 expression in carcinoma cells varies considerably between studies (8.7%–67.4%) (Table 6) [16171820]. Differences in the organ and carcinoma types, sample size, different antibody clones, scoring methods, and cutoff criteria may account for this discrepancy.…”

“…Any samples on which the pathologists did not agree were reviewed jointly at a multihead microscope and a consensus was reached. Percentages of TLE1 positive tumor cells and staining intensity were calculated for each sample as follows, using a modified scoring method [16]: 0, no staining or staining in <1% of the tumor cells; 1, staining in 1% to 10% of the cells (weak); 2, staining in 11% to 50% of the cells (moderate); and 3, staining in >50% of tumor cells (strong). TLE1 expression was categorized as low or no TLE1 expression (scores of 0–1) and high TLE1 expression (scores of 2–3).…”

“…TLE1 overexpression has been documented in some epithelial cancers, including gastric cancer, breast cancer, lung cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma [1617181920212223]. Conflicting results have been published on the function of TLE1 in some carcinomas.…”